June 2026

New Products

• Loncastuximab tesirine (Zynlonta) is an antibody‑drug conjugate (ADC) targeting CD19. The monoclonal immunoglobulin G1 kappa antibody component binds to human CD19, a transmembrane protein expressed on the surface of cells of B‑lineage origin. The small molecule component is SG3199, a pyrrolobenzodiazepine dimer and alkylating agent. Upon binding to CD19, loncastuximab tesirine is internalised followed by release of SG3199 via proteolytic cleavage. The released SG3199 binds to the DNA minor groove and forms highly cytotoxic DNA interstrand crosslinks, subsequently inducing cell death. Zynlonta monotherapy has provisional approval for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma after two or more lines of systemic therapy. It is not indicated for patients with primary central nervous system lymphoma. Zynlonta powder for infusion contains loncastuximab tesirine 10 mg and is available in packs of 1 vial. Each vial contains 5 mg/mL of loncastuximab tesirine after reconstitution.
   
• Pirtobrutinib (Jaypirca) is a reversible, noncovalent inhibitor of Bruton's tyrosine kinase (BTK). BTK is a signalling protein of the B‑cell antigen receptor and cytokine receptor pathways. In B‑cells, BTK signalling results in activation of pathways necessary for B‑cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK as well as BTK harbouring C481 mutations leading to inhibition of BTK kinase activity. Jaypirca, as monotherapy, is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who have been previously treated with a covalent BTK inhibitor. Jaypirca tablets contain pirtobrutinib 50 mg or 100 mg and are available in packs of 30 (50 mg) or 60 (100 mg).

New Presentation

• Sildenafil (citrate) (Azulvig) is now available as an oral suspension containing sildenafil 12.5 mg per 1 actuation (0.5 mL). The suspension has a total volume of 30 mL and is available in packs of 1 bottle.

New Indications

• Lurbinectedin (Zepzelca) in combination with atezolizumab, is now indicated for the maintenance treatment of extensive-stage small cell lung cancer (SCLC) in adult patients whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.
   
• Meningococcal polysaccharide conjugate A, C, Y and W‑135 vaccine (MenQuadfi) is now indicated for active immunisation of individuals from 6 weeks of age against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y.
   
• Obinutuzumab (rch) (Gazyva) is now indicated for the treatment of adult patients with active class III or IV, with or without concomitant class V, lupus nephritis (LN) who are receiving standard therapy.
   
• Vutrisiran (sodium) (Amvuttra) is now indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR‑CM).

Safety Related Changes

• Nirmatrelvir and ritonavir (Paxlovid) is no longer contraindicated in patients with severe renal impairment.

This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.